Lumosa Therapeutics Co., Ltd.

This Phase IIa trial tested a single dose of LT3001, a new drug, in 24 people who had an acute ischemic stroke within the past 24 hours. The main goal was to see if the drug causes dangerous bleeding in the brain compared to a placebo. Researchers also looked for early signs that…

This Phase 2 trial tested a drug called LT3001 in 89 people who had an acute ischemic stroke. Participants received either the drug or a placebo within 24 hours of their stroke. The study found no serious drug-related side effects, suggesting LT3001 is safe. Researchers are now l…

This study tested a single injection of a long-acting painkiller called SDE in 221 adults recovering from hemorrhoid surgery. Half received the drug and half a placebo. Researchers measured pain levels and how much extra pain medicine was needed over 48 hours. The goal was to see…

This Phase 1 trial tested the safety of LT3001, a potential clot-busting drug for acute ischemic stroke, in 65 healthy adults. Participants received multiple doses of LT3001 alone or with common stroke medications like aspirin and clopidogrel. The goal was to check for side effec…